AGM/EGMMay 21, 2026, 04:13 PM
Travere Therapeutics Stockholders Approve 3M Share Equity Plan Increase
AI Summary
Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares authorized for issuance by 3,000,000. Additionally, stockholders elected ten directors, provided advisory approval for named executive officer compensation, indicated a preference for annual advisory votes on executive compensation, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026.
Key Highlights
- Stockholders approved increasing the 2018 Equity Incentive Plan shares by 3,000,000.
- Ten directors were elected to serve until the 2027 Annual Meeting.
- Executive officer compensation received advisory approval with 73,711,670 votes for.
- Stockholders preferred annual advisory votes on executive compensation (75,003,558 votes).
- Ernst & Young LLP was ratified as the independent auditor for 2026 with 80,708,265 votes for.
- The total share reserve for the 2018 Equity Incentive Plan is now 25,384,114 shares.
Price Impact
More from TVTX